FDA Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products

标准简介

Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products[附网盘链接]是Food And Drug Administration于当前发布的FDA标准，适用于United States。

标准截图

 

标准文档说明

标准文档类型为Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products[附网盘链接]高清PDF版本（文字版），标准文档内可进行搜索，可以复制原文，可粘贴。

标准部分原文

Design and Analysis of Shedding Studies for Virus or Bacteria-

Based Gene Therapy and Oncolytic Products Guidance for Industry This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page. I. INTRODUCTION The Center for Biologics Evaluation and Research (CBER)/Office of Cellular, Tissue, and Gene Therapies (OCTGT) is issuing this guidance to provide you, sponsors of virus or bacteria-based 1 2

gene therapy products (VBGT products) and oncolytic viruses or bacteria (oncolytic products) with recommendations on how to conduct shedding studies during preclinical and clinical development. For purposes of this guidance, the term “shedding” means release of VBGT or oncolytic products from the patient through one or all of the following ways: excreta (feces); secreta (urine, saliva, nasopharyngeal fluids etc.); or through the skin (pustules, sores, wounds). Shedding is distinct from biodistribution because the latter describes how a product is spread within the patient’s body from the site of administration while the former describes how it is excreted or released from the patient’s body. Shedding raises the possibility of transmission of 3

VBGT or oncolytic products from treated to untreated individuals (e.g., close contacts and health care professionals). This guidance represents FDA’s current thinking on how and when shedding data should be collected for VBGT and oncolytic products during preclinical and 1

Gene therapy products are all products that mediate their effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and that are administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells in vivo or transferred to cells ex vivo before administration to the recipient. See section III. of FDA’s guidance entitled “Guidance for Industry: Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events” dated November 2006. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/cellularandgeneth

erapy/ucm072957.htm. 2 Oncolytic products refer to replication competent viruses or dividing bacteria that are used as therapeutic agents to mediate lysis of tumor cells. Some oncolytic products carry foreign genes (immune modifying genes, genes that enhance oncolysis etc.), and mediate part of their anti-tumor effect by transcription and/or translation of these foreign genes in the host. Hence, oncolytic products that carry foreign genes can also be classified as gene therapy products. 3

Transmission could occur if the VBGT or oncolytic product is shed in the form of intact viruses or bacteria but not when shed as viral or bacterial degradation products such as nucleic acid fragments.

网盘链接

百度网盘：https://pan.baidu.com/s/1QSifh_vZY0QkaLGhCtx0Kg
提取码：4p5k